J Thorac Oncol

• 

  Publication Venue For

  • Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial..  14:1266-1276. 2019
  • The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation..  14:1172-1183. 2019
  • Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). 2019
  • K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways..  14:606-616. 2019
  • Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032..  14:237-244. 2019
  • Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer..  14:298-303. 2019
  • Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma..  14:25-36. 2019
  • Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy: A Comparison Using the National Cancer Database..  14:107-114. 2019
  • Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States..  13:1842-1850. 2018
  • Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation..  13:1655-1667. 2018
  • Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy..  13:1294-1301. 2018
  • Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC..  13:1171-1182. 2018
  • New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center..  13:1189-1203. 2018
  • Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711)..  13:996-1003. 2018
  • Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017..  13:767-778. 2018
  • Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy..  13:660-675. 2018
  • Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis..  12:1814-1823. 2017
  • Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer..  12:1806-1813. 2017
  • Rethinking Autoantibody Signature Panels for Cancer Diagnosis..  12:1011-1014. 2017
  • Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance)..  12:843-849. 2017
  • Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance)..  12:704-713. 2017
  • The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients..  12:689-696. 2017
  • Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation..  12:368-374. 2017
  • ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology..  11:S250-S251. 2016
  • PS01.61: Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress: Topic: Medical Oncology..  11:S308-S309. 2016
  • PS01.76: Impact of Chemotherapy Intensity on Progression and Survival in Metastatic Non-Small Cell Lung Cancer: A Systematic Review: Topic: Medical Oncology..  11:S319. 2016
  • Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer..  11:1672-1681. 2016
  • Location of the Tumor is a "Central" Predictor of Nodal (N1) Upstaging..  11:e89-e90. 2016
  • 60PD Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PD-L1)..  11:S80-S81. 2016
  • Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE)..  11:361-369. 2016
  • The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification..  11:142-154. 2016
  • Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools..  10:1576-1589. 2015
  • Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography"..  10:e102. 2015
  • Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer..  10:1067-1075. 2015
  • Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer..  10:1099-1106. 2015
  • FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer..  10:897-902. 2015
  • Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer..  10:331-337. 2015
  • A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)..  10:143-147. 2015
  • Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma..  10:181-188. 2015
  • Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer..  9:1443-1448. 2014
  • Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study..  9:1354-1362. 2014
  • Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer..  9:1195-1201. 2014
  • Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data..  9:702-709. 2014
  • Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005..  9:512-518. 2014
  • CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer..  9:214-221. 2014
  • The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations..  9:141-143. 2014
  • A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer..  8:1510-1518. 2013
  • Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer..  8:1545-1550. 2013
  • A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904..  8:1043-1049. 2013
  • Impact of PET staging in limited-stage small-cell lung cancer..  8:899-905. 2013
  • Polymorphisms in mTORC1 genes modulate risk of esophageal squamous cell carcinoma in eastern Chinese populations..  8:788-795. 2013
  • Treatment modalities for T1N0 esophageal cancers: a comparative analysis of local therapy versus surgical resection..  8:796-802. 2013
  • Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer..  8:744-752. 2013
  • Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206..  8:102-108. 2013
  • Cigarette smoking associated with lung adenocarcinoma in situ in a large case-control study (SFBALCS)..  7:1352-1360. 2012
  • Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy..  7:1141-1147. 2012
  • Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)..  7:906-912. 2012
  • CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304..  7:649-654. 2012
  • Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report..  7:755-759. 2012
  • Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases..  7:723-730. 2012
  • Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer..  7:376-381. 2012
  • Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib..  6:2135-2137. 2011
  • Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304..  6:1902-1906. 2011
  • Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest..  6:1726-1732. 2011
  • The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer..  6:1687-1690. 2011
  • The use of electrocautery as the primary ablation modality for malignant and benign airway obstruction..  6:1516-1520. 2011
  • Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study..  6:1432-1434. 2011
  • Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer..  6:1267-1273. 2011
  • Disparities in lung cancer staging with positron emission tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) study..  6:875-883. 2011
  • Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer..  6:781-785. 2011
  • How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems..  6:757-761. 2011
  • International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma..  6:244-285. 2011
  • Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer..  6:384-386. 2011
  • A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307..  5:1655-1661. 2010
  • National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers..  5:1502-1506. 2010
  • Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)..  5:1644-1648. 2010
  • Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial..  5:1382-1390. 2010
  • Tumor necrosis and cavitation after stereotactic body radiation therapy..  5:1100-1102. 2010
  • Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633..  5:810-817. 2010
  • A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602)..  5:380-384. 2010
  • Preoperative radiation therapy and chemotherapy for pulmonary blastoma: a case report..  5:282-283. 2010
  • Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure..  5:211-214. 2010
  • Molecular analysis-based treatment strategies for the management of non-small cell lung cancer..  4:S1029-S1039. 2009
  • Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer..  4:1117-1125. 2009
  • Giant thoracic liposarcoma treated with induction chemotherapy followed by surgical resection..  4:768-769. 2009
  • A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104..  4:220-226. 2009
  • Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial..  4:198-202. 2009
  • Formation of a bronchoesophageal fistula following concurrent radiation and chemotherapy for lung cancer in the setting of Behçet's disease..  3:1361-1362. 2008
  • Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430..  3:1301-1307. 2008
  • Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)..  3:1159-1165. 2008
  • Intrathoracic desmoid tumor: brief report and review of literature..  3:656-659. 2008
  • Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904..  3:417-421. 2008
  • Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901..  3:158-162. 2008
  • Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project..  3:6-12. 2008
  • Frequency and prognostic significance of preoperatively detected enlarged regional lymph nodes in patients with pathological stage I non-small cell lung cancer following resection..  2:1103-1106. 2007
  • The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer..  2:686-693. 2007
  • Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002..  2:645-651. 2007
  • Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238..  2:619-625. 2007
  • A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer..  2:520-525. 2007
  • Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence..  2:499-505. 2007
  • A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy..  2:210-220. 2007
  • Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria..  1:S13-S19. 2006
  • Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment..  1:S20-S26. 2006
  • Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care..  1:692-696. 2006
  • Targeting anemia in patients with lung cancer..  1:716-725. 2006
  • Integration of biomarkers and imaging..  1:78-80. 2006
  • 102P: Ablative robotic radiosurgery for inoperable patients with stage IA-IB non small cell lung cancer. 2016